Aileron Therapeutics Stock Performance
| ALRN Stock | USD 2.46 0.01 0.40% |
On a scale of 0 to 100, Aileron Therapeutics holds a performance score of 2. The firm shows a Beta (market volatility) of 0.27, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Aileron Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aileron Therapeutics is expected to be smaller as well. Please check Aileron Therapeutics' downside variance, and the relationship between the sortino ratio and accumulation distribution , to make a quick decision on whether Aileron Therapeutics' price patterns will revert.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Aileron Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Aileron Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.63 | Five Day Return (8.42) | Year To Date Return (19.87) | Ten Year Return (98.84) | All Time Return (98.84) |
Last Split Factor 1:20 | Last Split Date 2022-11-11 |
1 | University of Texas Texas AM Investment Management Co. Makes New Investment in Aileron Therapeutics, Inc. - MarketBeat | 09/03/2024 |
2 | Disposition of 17064 shares by Musso Alan A of Aileron Therapeutics at 4.63 subject to Rule 16b-3 | 09/13/2024 |
3 | Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - StockTitan | 10/31/2024 |
4 | Disposition of 6291 shares by University Of Texastexas Am Investment Management Co of Aileron Therapeutics at 3.3 subject to Rule 16b-3 | 11/07/2024 |
5 | Aileron Therapeutics Stock Declines Amidst Mixed Sector Performance | 11/11/2024 |
6 | Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com | 11/14/2024 |
7 | Aileron Therapeutics Reports Q3 2024 Financial Results - MSN | 11/20/2024 |
| Begin Period Cash Flow | 5.2 M |
Aileron |
Aileron Therapeutics Relative Risk vs. Return Landscape
If you would invest 237.00 in Aileron Therapeutics on August 28, 2024 and sell it today you would earn a total of 9.00 from holding Aileron Therapeutics or generate 3.8% return on investment over 90 days. Aileron Therapeutics is currently generating 0.2286% in daily expected returns and assumes 6.0267% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than Aileron, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aileron Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aileron Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aileron Therapeutics, and traders can use it to determine the average amount a Aileron Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0379
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ALRN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.03 actual daily | 53 53% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 2 98% of assets perform better |
Based on monthly moving average Aileron Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aileron Therapeutics by adding it to a well-diversified portfolio.
Aileron Therapeutics Fundamentals Growth
Aileron Stock prices reflect investors' perceptions of the future prospects and financial health of Aileron Therapeutics, and Aileron Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aileron Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 36.03 M | ||||
| Shares Outstanding | 21.67 M | ||||
| Price To Earning | (0.31) X | ||||
| Price To Book | 1.06 X | ||||
| Gross Profit | (17.01 M) | ||||
| EBITDA | (15.61 M) | ||||
| Net Income | (15.73 M) | ||||
| Cash And Equivalents | 32.38 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 48 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.51 X | ||||
| Book Value Per Share | 1.41 X | ||||
| Cash Flow From Operations | (19.81 M) | ||||
| Earnings Per Share | (2.88) X | ||||
| Market Capitalization | 53.3 M | ||||
| Total Asset | 106.01 M | ||||
| Retained Earnings | (288.52 M) | ||||
| Working Capital | 13.88 M | ||||
| Current Asset | 3.43 M | ||||
| Current Liabilities | 459 K | ||||
About Aileron Therapeutics Performance
By examining Aileron Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Aileron Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Aileron Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.77) | (0.81) | |
| Return On Capital Employed | (0.16) | (0.17) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (2.28) | (2.17) |
Things to note about Aileron Therapeutics performance evaluation
Checking the ongoing alerts about Aileron Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aileron Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aileron Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (15.73 M) with loss before overhead, payroll, taxes, and interest of (17.01 M). | |
| Aileron Therapeutics currently holds about 32.38 M in cash with (19.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36. | |
| Aileron Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Aileron Therapeutics Reports Q3 2024 Financial Results - MSN |
- Analyzing Aileron Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aileron Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aileron Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aileron Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aileron Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aileron Therapeutics' stock. These opinions can provide insight into Aileron Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aileron Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Aileron Stock, please use our How to Invest in Aileron Therapeutics guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aileron Therapeutics. If investors know Aileron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aileron Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Return On Assets (0.26) | Return On Equity (0.44) |
The market value of Aileron Therapeutics is measured differently than its book value, which is the value of Aileron that is recorded on the company's balance sheet. Investors also form their own opinion of Aileron Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aileron Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aileron Therapeutics' market value can be influenced by many factors that don't directly affect Aileron Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aileron Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aileron Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aileron Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.